The study was funded, in part, by the National Institutes of Health (grants P30 AI036214, UM1 AI068634, UM1 AI068636, UM1 AI106701) and the James B
Other companies are working on their own weight-loss pills: Eli Lilly, which makes Zepbound, is developing a GLP-1 pill, orforglipron, for weight loss and type 2 diabetes, with FDA approval anticipated for March 2026
Lilly claims retatrutide delivers bariatric-level weight loss in trial Lilly claims retatrutide delivers bariatric-level weight loss in trial In Business news Follow this topic Bookmark Record learning outcomes Mounjaro manufacturer Lilly has said retatrutide, a triple hormone receptor agonist product currently in development, helped patients achieve powerful weight loss in a Phase 3 clinical trial
Best Injection Sites Choosing the right injection site is just as important as the technique
Other conditions such as thyroid disorders, infections, anxiety, or other medications can also cause similar symptoms